BeiGene, Ltd. (BGNE)
BeiGene, Ltd. (BGNE)
$122.33 USD
Updated Jul 17 10:04am
Add BGNE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all “A” rated Strong Buy stocks
BGNE News Stream
| Event/Time | News Detail | Start | End | Change | |||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Top Stories View All
The Expansion Continues for Aurora Cannabis (ACB)
Hexo Corp. (HEXO) began trading on the NYSE today, here’s what it means for the stock
Best & Worst Performing Stock Industries for July 16, 2019
Best & Worst Performing Small Cap Stocks for July 16, 2019
Best & Worst Performing Large Cap Stocks for July 16, 2019
View All Top StoriesBeiGene, Ltd. (BGNE) Company Bio
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.
BGNE Stock Chart More Charts
BGNE Price/Volume Stats
| Current price | $122.33 |
| Prev. close | $121.17 |
| Day low | $121.18 |
| Day high | $122.37 |
| 50-day MA | $124.22 |
| 200-day MA | $131.28 |
| 52-week high | $194.56 |
| 52-week low | $105.19 |
| Volume | 20,527 |
| Avg. volume | 319,433 |
| Dividend yield | N/A |
| Market Cap | 5.71B |
BGNE Returns
| 1-mo | 7.32% |
| 3-mo | 2.11% |
| 6-mo | -14.62% |
| 1-year | -25.46% |
| 3-year | 314.12% |
| 5-year | N/A |
| YTD | -12.78% |
| 2018 | 43.53% |
| 2017 | 221.87% |
| 2016 | N/A |
| 2015 | N/A |
| 2014 | N/A |
Loading social stream, please wait...